Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria.

Literature DB >> 2953303

Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria.

N X Chin, N M Neu, P Labthavikul, G Saha, H C Neu.

Abstract

A-56268 was compared with erythromycin, roxithromycin (RU 28965), and perorally administered antimicrobial agents. Its in vitro activity was similar to that of erythromycin and slightly greater than that of roxithromycin, with beta-hemolytic streptococci and Streptococcus pneumoniae inhibited by less than 2 micrograms of A-56268 per ml (50% inhibited by 0.06 microgram/ml). Streptococcus pyogenes, S. agalactiae, S. Pneumoniae, and S. faecalis resistant to erythromycin were resistant to A-56268, and 4 micrograms/ml inhibited 90% of Haemophilus influenzae isolates.

Entities: Chemical Species

Mesh：

Substances：

Year: 1987 PMID： 2953303 PMCID： PMC174754 DOI： 10.1128/AAC.31.3.463

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

4 in total

1. In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

Authors: T Barlam; H C Neu
Journal: Antimicrob Agents Chemother Date: 1984-04 Impact factor: 5.191

2. In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.

Authors: R N Jones; A L Barry; C Thornsberry
Journal: Antimicrob Agents Chemother Date: 1983-08 Impact factor: 5.191

Review 3. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2).

Authors: J A Washington; W R Wilson
Journal: Mayo Clin Proc Date: 1985-04 Impact factor: 7.616

4. Effect of several components of anaerobic incubation on antibiotic susceptibility test results.

Authors: J E Rosenblatt; F Schoenknecht
Journal: Antimicrob Agents Chemother Date: 1972-05 Impact factor: 5.191

4 in total

14 in total

Review 1. New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors: H A Kirst; G D Sides
Journal: Antimicrob Agents Chemother Date: 1989-09 Impact factor: 5.191

2. Comparative in vitro activity of the new macrolide A-56268 against anaerobic bacteria.

Authors: H M Wexler; S M Finegold
Journal: Eur J Clin Microbiol Date: 1987-08 Impact factor: 3.267

3. Ancillary benefits of Mycobacterium avium-intracellulare complex prophylaxis with clarithromycin in HIV-infected patients.

Authors: H Jablonowski; G Fätkenheuer; M Youle; T Newell; S Lines; J C Craft
Journal: Drugs Date: 1997 Impact factor: 9.546

Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria.

1. In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

2. In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.

Review 3. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2).

4. Effect of several components of anaerobic incubation on antibiotic susceptibility test results.

Review 1. New directions for macrolide antibiotics: structural modifications and in vitro activity.

2. Comparative in vitro activity of the new macrolide A-56268 against anaerobic bacteria.

3. Ancillary benefits of Mycobacterium avium-intracellulare complex prophylaxis with clarithromycin in HIV-infected patients.

4. Penetration of clarithromycin into lung tissues from patients undergoing lung resection.

5. In vitro activity of YM133, a new semisynthesized macrolide.

Review 6. Clarithromycin clinical pharmacokinetics.

Review 7. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

8. Comparative in vitro activity of clarithromycin. Spanish Collaborative Group.

9. Pharmacokinetics of a clarithromycin suspension in infants and children.

10. In vitro activity of MC-352, a new 16-membered macrolide.